A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer
According to different location of the primary lesion,the subject can be allocated to two
sub-groups:
The patient with upper or middle thoracic esophageal cancer may be assigned to two
field(T)-total mediastinal lymphadenectomy group,which is control group in this study or
three field lymphadenectomy-Abdominal + mediastinal + cervical lymphadenectomy group,which
is study group in this study randomly.
The patient with lower thoracic esophageal cancer may be assigned to three different
groups:two field(S)-standard mediastinal lymphadenectomy group, which is control group in
this study,or two field(T)-total mediastinal lymphadenectomy,which is the first study group
in this study,or three field lymphadenectomy group which is the second study group in this
study randomly.
After the operation,the patient whose primary lesion is completely(R0) resected will be
assigned to adjuvant chemotherapy group or interview group randomly.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
survival rate
Disease-free survival overall survival
5 years
Yes
Peng Lin, Professor
Principal Investigator
651, Dongfeng Road East, Guangzhou, P. R. China
China: Ethics Committee
2007044
NCT01137123
April 2010
September 2016
Name | Location |
---|